Settlement expense - - (160) (883)
Loss before minority interest (48,507) (27,832) (100,583) (100,219)
Minority interest in net loss
of subsidiary 36 - 36 -
Net loss (48,471) (27,832) (100,547) (100,219)
Preferred stock beneficial
conversion feature (3,918) - (8,301) -
Preferred stock dividends (214) - (395) -
Net loss attributable to
common shareholders $(52,603) $(27,832) $(109,243) $(100,219)
Basic and diluted net loss per
common share $(1.09) $(1.00) $(2.55) $(3.93)
Shares used in calculation of
basic and diluted net loss per
common share (1) 48,202 27,890 42,873 25,533
Balance Sheet Data: (amounts in thousands)
September 30, December 31,
2007 2006
Cash and cash equivalents, securities (unaudited)
available-for-sale and interest receivable $38,313 $54,407
Working capital (33,916) 30,166
Total assets 84,953 101,821
Convertible debt 150,128 166,178
Accumulated deficit (1,070,351) (961,108)
Shareholders' deficit (119,348) (101,604)
(1) Amounts reflect a one-for-four reverse stock split of our common stock
effective April 15, 2007.
| SOURCE Cell Therapeutics, Inc. Copyright©2007 PR Newswire. All rights reserved |